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Abstract
Background: Site-1 protease (S1P) is the key enzyme required for activation of the sterol regulatory element binding
proteins (SREBPs) that govern lipid synthesis. While S1P has been speculated to influence plasma apoB-containing
lipoprotein (Blp) metabolism, there has been little investigative work. LDL receptor (LDLR) is the major receptor
for clearing plasma LDL cholesterol (LDL-c). Proprotein convertase subtilisin kexin type 9 (PCSK9) modulates LDL-c
through post-translational degradation of the LDLR.
Methods: A hepatic-specific knockdown (KD) of S1P was achieved using floxed S1P mouse models (S1Pf/f and
LDLR-/-S1Pf/f) and hepatic expression of Cre recombinase. Lipids were measured in total plasma and size fractionated
plasma using colorimetric assays. Realtime polymerase chain reaction, western blotting and ELISA were used to determine
hepatic expression of key genes/protein. Plasmid mediated overexpression and siRNA mediated knockdown of genes
were performed in mouse primary hepatocytes to determine the mechanistic basis of PCSK9 gene regulation.
Results: A hepatic-specific KD of S1P resulted in a 45 % and 38 % reduction in plasma total cholesterol and
triglyceride levels, respectively. Hepatic S1P KD had a minimal effect on plasma Blp cholesterol (Blp-c) in S1Pf/f
mice, despite significantly reducing VLDL secretion. Notably, hepatic S1P KD decreased the LDL receptor (LDLR) mRNA
expression by 50 %. However, the reduction in LDLR protein levels was less than that of mRNA expression, especially
under fed conditions. Further assessment of hepatic S1P deficiency revealed that it increased LDLR protein stability in
vivo. Mechanistically, hepatic S1P KD was shown to decrease the liver and plasma levels of the protein proprotein
convertase subtilisin/kexin type 9 (PCSK9), which degrades LDLR protein. This effect was more prominent in the fed
condition and sufficient to account for the discordance in LDLR mRNA and protein levels. Furthermore, hepatic S1P
was shown to regulate PCSK9 expression through activation of the SREBPs. In the LDLR-/- background, hepatic S1P KD
significantly reduced Blp-c levels.
Conclusion: Hepatic S1P is a physiological modulator of plasma Blp metabolism through its regulation of LDLR and
PCSK9. Hepatic S1P is a valid target for lowering plasma Blp-c levels in the situation where LDLR function is compromised.
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Background
Site 1 protease (S1P, also known as membrane-bound
transcription factor peptidase, site 1), belongs to the pro-
protein convertase (PCSK) family. The S1P precursor
undergoes an auto-catalytic processing in the ER, involv-
ing sequential cleavage at two sites, to generate two active
mature forms, B and C [1]. The mature S1P forms (hence-
forth referred to as S1P) then become anchored to the
Golgi membrane [1]. S1P cleaves and activates membrane-
bound unprocessed transcription factors that have been
transported to the Golgi [2–5]. For example, S1P is one of
the key enzymes required for release of the transcription-
stimulating domains of sterol regulatory element binding
proteins (SREBP1a, SREBP1c and SREBP2) in vitro and in
vivo [6]. SREBPs are synthesized as inactive precursors
bound to endoplasmic reticulum (ER) in complex with
SCAP, an ER to Golgi transport protein.
SREBPs are the best characterized of the transcrip-
tion factors which regulate de novo synthesis of fatty
acids and cholesterol. Although SREBP1 and 2 bind
to the same consensus sequence, for unknown rea-
sons SREBP1c chiefly regulates the synthesis of fatty
acids by enhancing transcription of the genes encoding
acetyl CoA carboxylase, fatty acid synthase, stearoyl CoA
desaturase-1 and other genes related to fatty acid synthesis
[7]. SREBP2, on the other hand, controls the synthesis
of cholesterol by increasing the levels of mRNAs for
all known enzymes of the cholesterol biosynthetic
pathway [7]. When S1P is inactivated or inhibited [6, 8],
levels of the active forms of the SREBPs in hepato-
cytes fall markedly, along with a decline in all SREBP
target mRNAs, and the rates of synthesis of fatty
acids and cholesterol decline by approximately 90 %
and 75 %, respectively [6, 8].
Interestingly, S1P has been shown to influence plasma
lipid levels in three different mouse models fed a chow
diet: (i) a hypomorphic S1P mutation reduced total chol-
esterol (TC) levels by 50 % but not triglyceride levels
(TG) [9]; (ii) acute disruption of S1P in hepatocytes and
cells of myeloid lineage, mediated by an inducible Cre
recombinase, led to a decline in plasma TC and TG
levels [6]; (iii) pharmacological inhibition of S1P signifi-
cantly decreased TC and TG concentrations (8). While
it has been speculated that S1P affects plasma apoB-
containing lipoprotein (Blp) metabolism, there has been
little investigative work. This is of particular importance
since lowering plasma Blp-c levels is the cornerstone of
current management of cardiovascular disease.
The mechanism(s) by which liver S1P regulates plasma
lipid metabolism is (are) not fully understood. Since hep-
atic S1P inhibition decreases the activation of SREBPs
and hence reduces de novo lipid synthesis, the reduced
lipid substrates should reduce VLDL assembly and lead
to lower VLDL secretion rates. One would expect an
associated decrease in the plasma cholesterol levels in
Blps, including VLDL, IDL and LDL. However, activa-
tion of the SREBP pathway by constitutively expressing
the SREBP transcription stimulating domains also lowers
plasma TC and TG levels [10–12] , suggesting that the
reduced plasma lipid levels following S1P deficiency/in-
hibition cannot be exclusively explained by changes in
de novo lipid synthesis.
Potential mechanisms are many, since many genes in
addition to those involved in fatty acid and cholesterol
biosynthetic pathways are regulated by the SREBPs [13],
including those for the LDL receptor (LDLR) and pro-
protein convertase subtilisin/kexin type 9 (PCSK9). S1P
is also the candidate protease for activation of two other
major transcription factors involved in lipid metabolism,
activating transcription factor 6 (ATF6) [3], and cyclic
AMP-responsive element binding protein-H (CREBH)
[4]. S1P could thus affect plasma lipid metabolism by
pathways in addition to those involving the SREBPs.
The major questions underlying this research are: does
inhibition of hepatic S1P decrease plasma Blp-c levels? If
so, what is the molecular mechanism? We evaluated the
role of hepatic S1P in plasma Blp-c metabolism using
different mouse models of hepatic S1P deficiency. We
showed that hepatic S1P inhibition lowers plasma Blp-c
levels in LDLR-/-S1Pf/f but not S1Pf/f mice. We found
that hepatic S1P, by controlling the activation of SREBPs,
is a physiological modulator of liver LDLR and PCSK9.
These two regulations are critical for fine-tuning LDLR
function and hence plasma Blp-c levels.
Methods
Materials
All reagents and chemicals were obtained from Fisher
Scientific (Pittsburgh, PA) and Sigma Aldrich (St. Louis,
MO) unless otherwise stated.
Animals
All procedures were conducted in conformity with the
United States Public Health Service Policy on Humane
Care and Use of Laboratory Animals and approved by
the Institutional Animal Care and Use Committee of
SUNY Downstate Medical Center. All mice used have a
C57Bl/6 J background. S1P heterozygous floxed mice
were obtained from The Jackson Laboratory (Bar Harbor,
Maine) [6] and bred to generate S1P homozygous floxed
mice (S1Pf/f ). Mice were studied at 8-12 weeks of age.
Studies were carried in both male and female mice and
similar results were obtained. To achieve acute knock-
down (KD) of S1P in the adult mouse liver, S1Pf/f mice
were intravenously administered adenovirus-expressing
Cre under the CMV promoter (S1Pf/fCre mice). They
were studied 4–7 days after virus administration. Control
group S1Pf/f mice were intravenously administered
Basu et al. Nutrition & Metabolism  (2015) 12:35 Page 2 of 14
adenovirus expressing either firefly luciferase (S1Pf/fLuci
mice) or adenovirus not expressing any protein
(S1Pf/fEmpty mice). 1 × 1011 viral particles were injected
per mouse. Albumin Cre mice were purchased from The
Jackson Laboratory [14]. S1Pf/f mice were crossed with
these mice to obtain mice with liver-specific ablation of
S1P (L-S1P). S1Pf/f mice were bred with LDLR knockout
(LDLR-/-) mice to obtain LDLR-/-S1Pf/f mice. Primer se-
quences for genotyping were obtained from The Jackson
Laboratory.
Mice were kept on a 7 AM-7 PM lighting schedule
with free access to water and a standard laboratory chow
diet unless otherwise indicated. Ad libitum fed mice
were sacrificed between 9 AM-10 AM. For overnight
fasting studies, the chow diet was withdrawn from
6 PM-9 AM. For collection of plasma, mice were anes-
thetized using isoflurane and blood was collected from
the retro-orbital plexus in heparinized micro-capillary
tubes, centrifuged at 10,000 × g at 4 °C, used immedi-
ately and/or stored at −20 °C. For organ collection, anes-
thetized mice were perfused with PBS to remove blood
and then livers and other tissues were collected and snap
frozen in liquid nitrogen or placed in dry ice and then
stored at −80 °C.
RNA isolation, cDNA synthesis and real-time PCR
RNA was isolated from livers or cells using the GeneJet
RNA isolation kit (Thermo Scientific, Waltham, MA).
RNA concentration was measured using the Nanodrop
2000 (Thermo Scientific, Waltham, MA) and 1.5 μg
RNA per sample was used for cDNA synthesis using the
Verso cDNA kit (Thermo Scientific, Waltham, MA).
cDNA was amplified with gene specific primers and de-
tected with the Absolute Blue SYBR Green ROX Mix
(Thermo Scientific, Waltham, MA) in the StepOne Plus
Realtime PCR machine (Applied Biosystems, Grand Is-
land, NY). 18S RNA was used as an invariant control.
The standard curve method of analysis for RNA quanti-
tation was utilized using dilutions of corresponding
cDNA plasmids as the standards. The primer sequences
for S1P, PCSK9, LDLR, SREBP1c, SREBP2, ACC1, FAS
and HMGCoA reductase were as described in a previous
publication [6]. All other primer sequences for real-time
PCR were obtained from the Primer Bank (http://
pga.mgh.harvard.edu/primerbank/).
Western blot analysis
Liver tissue from mice was homogenized in RIPA buffer
supplemented with Protease Inhibitor Cocktail from
Sigma (St. Louis, MO) using a QIA Tissue Lyser (Qiagen,
Valencia, CA). The homogenates were centrifuged at
14,000 rpm for 15 min at 4 °C and the supernatants col-
lected. Protein concentration was measured using a BCA
kit from Pierce (Rockford, IL). Supernatant (50 μg protein)
was combined with 4 × concentrated SDS loading buffer
and reducing agent and heated at 80 °C for 10 min. The
proteins were separated on 4–20 % SDS PAGE gels from
Pierce (Rockford, IL), transferred electrophoretically to
nitrocellulose membranes, blocked with 5 % bovine serum
albumin and probed with the following primary antibodies
(Abs): anti-LDLR from R&D Biosciences (Minneapolis,
MN); anti-GAPDH from Epitope Biotech Inc (Burnaby,
B.C., Canada); anti-S1P from Santa Cruz Biotech Inc
(Santa Cruz, CA); anti-actin from Genscript (Piscataway,
NJ). Horse radish peroxidase conjugated secondary Abs
were obtained from Jackson Immunoresearch (West
Grove, PA) and the visualized using the ECL Super Signal
West Pico or Femto reagent from Pierce (Rockford, IL).
Bands were scanned using a Microtek ScanMaker 5950
(Microtek, Santa Fe Springs, CA) and quantified using
Image-Pro Plus 6.0 (Media Cybernetics, Warrendale, PA).
Lipid analysis
Total cholesterol and triglyceride were determined
using commercially available kits from Fisher Scientific
(Pittsburgh, PA). Lipoprotein profiles in pooled plasma
samples were obtained by fast-protein liquid chroma-
tography (FPLC) using a gel filtration column as
described [15, 16], each sample comprising equal
amounts of plasma from each of the mice constituting
an experimental group.
VLDL-TG production in vivo
Four-hour fasted mice were injected intraperitoneally
with poloxamer 407 (P407) dissolved in PBS. P407 in-
hibits lipoprotein lipase, endothelial lipase and hepatic
lipase activities, preventing the degradation of plasma
TG-rich lipoproteins, which build up in the circulation.
Blood was collected before (0 h) and at 1, 2, 4 and 6 h
post P407 injection and plasma TG were measured.
Plasma PCSK9 measurements
The Circulex Mouse PCSK9 ELISA kit from MBLI
(Woburn, MA) and the Mouse PCSK9 Quantikine kit
from R&D Biosystems (Minneapolis, MN) were used
according to the manufacturers’ instructions.
Hepatocyte isolation and culture
S1Pf/f mice (transduced with either Ad-Luciferase or Ad-
Cre) were anesthetized with an intraperitoneal injection
of Ketamine (100 mg/kg) and Xylazine (10 mg/kg). Each
mouse was perfused with Hank’s balanced salt solu-
tion (buffered with Hepes to a final concentration of
10 mM, pH 7.4) for 5 min through the inferior vena
cava using a MP II Mini-Peristaltic Pump (Harvard
Apparatus, Holliston, MA) at a setting of 6 ml/min until
the liver was free of blood. The liver was then perfused with
collagenase type I (Worthington Biochemicals, Lakewood,
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NJ) added at 0.4 mg/ml to 1 × Hank’s solution and incu-
bated for 15 min. The collagenase digested liver was trans-
ferred into 25 ml of ice-cold William’s Medium E from
Sigma Aldrich (St. Louis, MO). The liver capsule was cut
open, hepatocytes were dispersed into the media with blunt
forceps, filtered through a 70 μm filter ( BD Bioscience,
Mississauga, ON) and combined with 25 ml of Percoll solu-
tion (2.5 ml of 10 × Hank’s solution plus 22.5 ml of Percoll).
The cell suspension was centrifuged at 180 × g for 6 min to
obtain live cells as a pellet. The pellet was washed with
25 ml of William’s Medium E solution to remove
traces of Percoll. The washed hepatocytes were then
resuspended in DMEM containing 10 % FBS. Cell via-
bility as checked by Trypan Blue exclusion was ap-
proximately 90 %. Hepatocytes were then plated in
collagen-coated plates (BD Bioscience, San Jose, CA).
After 2 h incubation at 37 °C with 5 % CO2 when
live cells had attached, the culture media was changed
and fresh DMEM with10% FBS added [15].
siRNA transfection
siGenome Smartpool siRNAs were obtained from
Dharmacon (Pittsburgh, PA) and transfected into pri-
mary hepatocytes at 40 nM final concentration using
the Lipofectamine 2000 transfection reagent from
Invitrogen (Grand Island, NY) [17]. Non-targeting
scrambled siRNAs were used as controls and were
denoted as siScr. Hepatocytes were collected for RNA
isolation 56 h post transfection.
Luciferase constructs and assays
The PCSK9 promoter regions (1 kb and 3 kb starting at
the transcription site) [18] were amplified from mouse
liver genomic DNA and cloned into a Gaussia luciferase
reporter construct (New England Biolabs (NEB), Ips-
witch, MA). All plasmid constructs were verified by
DNA sequencing prior to transfection in cells. The
Cypridina luciferase construct from NEB was used as
the control plasmid for in vitro dual reporter assays.
Gaussia and Cypridina luciferases are secreted into the
cell culture media. Plasmids were transfected into pri-
mary hepatocytes with Lipofectamine 2000 [19]. For dual
luciferase measurements, cell culture media were col-
lected 48 h post transfection. For most studies, 10 μl of
media was used to measure Gaussia and Cypridina activ-
ities and the ratio of Gaussia/Cypridina activities was
calculated as an indicator of PCSK9 promoter activity.
DiI-LDL binding and uptake
Fluorescent DiI-LDL, Biomedical Technologies, Inc.
(Stoughton, MA) was diluted in serum free DMEM
(5ug/ml), added to hepatocytes and incubated at 4 °C
for 2 h for binding and at 37 °C for 3 h for uptake [20].
The media was then removed, cells were washed gently
with PBS and then lysed in RIPA buffer. The lysate was
centrifuged at 12,000 rpm for 5 min and the fluores-
cence in the supernatant quantified using a Spectramax
M2 plate reader. The values were normalized to the
protein concentration of the cell lysates.
Nuclear run-on assay
Intact nuclei were isolated from murine primary hepato-
cytes and an in vitro nuclear run-on assay was carried out
using biotinylated UTP from Roche (Indianapolis, IN).
Total RNA was isolated and the newly synthesized RNA
which was biotinylated was pulled down using streptavidin
magnetic beads Pierce (Rockford, IL). Beads were washed
rigorously and then used for cDNA synthesis. Real-time
PCR was used to quantify cDNA from newly synthesized
PCSK9 pre-mRNA and 18S mRNA [21].
Statistical analyses
Values are expressed as the mean ± standard deviation
(SD) of triplicate determinations. Mice experiments were
repeated three times or more to confirm the consistency
of results. Comparisons between two groups were analyzed
by the unpaired Student’s t test. Comparisons among mul-
tiple mouse groups were analyzed by ANOVA followed by
unpaired Student’s t tests if necessary to determine
significant differences.
Results
Generation of hepatic S1P KD models S1Pf/f mice de-
scribed by Yang et al. [6] have about 20 % of the S1P
mRNA levels of wild-type (WT) mice likely due to the
neo cassette interfering with transcription of S1P. How-
ever S1Pf/f mice are indistinguishable from WT mice in
all other respects including plasma lipid profile [6]. To
determine the physiological role of hepatic S1P in regu-
lating plasma lipid and lipoprotein levels, we have used
S1Pf/f mice and knocked down S1P using two well-
accepted approaches: (a), S1Pf/f Cre, a model of acute
hepatic S1P knockdown (KD) via adenovirus-mediated
Cre expression, and (b), L-S1P mice (S1Pf/f crossed
with Albumin-Cre), a model of liver-specific S1P KD
via a Cre transgene under the control of the albumin
promoter. As expected, the S1P gene, when sub-
jected to Cre-induced recombination, produced a
shorter nonfunctional transcript (Fig. 1a). Levels of
the full-length hepatic S1P transcript were reduced
compared with those of S1Pf/f controls (Table 1, columns
1 and 2). The reduction in S1P mRNA expression
was further confirmed in freshly isolated primary he-
patocytes (Fig. 1b).
Hepatic S1P KD lowered plasma TC and TG but
showed minimal effect on plasma Blp-c levels S1Pf/f
Cre and L-S1P mice have similar knockdown of S1P in
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the liver and gave similar results with respect to effects
on plasma lipid phenotypes (Table 1, columns 1 and 2;
Table 2). We have focused on the S1Pf/f Cre mice model
as it eliminates the gene in the adult mice and mimics
drug intervention. In contrast, albumin cre mice express
cre right after birth.
The physiological effect of hepatic S1P KD on plasma
lipid levels was investigated following ad libitum feeding.
In the S1Pf/f Cre mice, 45 % and 38 % reductions in
plasma TC and TG levels, respectively, were observed
compared with S1Pf/fLuci controls (Table 1, columns 1
and 2). These results are in agreement with published
work indicating that hepatic S1P is a major regulator of
plasma lipids [6].
S1P KD in hepatocytes has been shown to reduce fatty
acids and cholesterol secretion in vitro [6]. We hypothe-
sized that hepatic S1P would reduce VLDL secretion in
vivo. VLDL secretion was studied in S1Pf/f Cre and S1Pf/f
Fig. 1 Hepatic S1P KD and plasma lipid levels. Hepatic S1P KD was verified by (a), Reverse transcriptional PCR analysis of liver cDNA using primers
that binds to sequence outside of the floxed sites; (b), Real-time PCR analysis of S1P KD in hepatocytes from S1Pf/fCre and WT control mice. N = 4,
each data point represents the mean +/- S.D., * denotes p < 0.05; (c), VLDL-TG secretion study. Four-hour fasted female S1Pf/f Luci and S1Pf/fCre mice
were injected intraperitoneally with poloxamer 407 (P407) and plasma TGs monitored over a period of 6 h. N = 4, 6–8 weeks of age each data point
represents the mean +/- S.D., * denotes p < 0.05; (d-e), Lipid measurements were carried out on gel filtration fractions from the pooled plasma samples.
This experiment was repeated three times and similar results were obtained
Table 1 Phenotypic comparison of S1Pf/f, and LDLR-/-S1Pf/f after
hepatic S1P KD
Parameter S1Pf/f LDLR-/-S1Pf/f
Ad-Luci Ad-Cre Ad-Luci Ad-Cre
Number and sex 4 females 4 females 4 females 4 females
S1P mRNA %a 100 ± 7.8 23.3 ± 3.0** 100 ± 3.8 29 ± 15.4**
TC, mg/dl 78.5 ± 13.2 43.7 ± 7.0* 180.8 ± 31.9 109.9 ± 14.4*
TG, mg/dl 111.2 ± 20.5 69.5 ± 7.0* 107.3 ± 36.9 73.8 ± 16.6*
Female mice (6–8 weeks of age) were injected i.v. with either Ad-Luci or
Ad-Cre as described in Methods. Eight days after the last injection, blood was
obtained. Each value represents the mean ± the SD of four mice. The statistical
significance (Student’s t test) between Ad-Luci and corresponding Ad-Cre mice
was calculated. *P < 0.05; and **P < 0.01. afull length S1P mRNA expression is
expressed as a % of the corresponding Ad-Luci value
Table 2 Phenotypic comparison of S1Pf/f and L-S1P
Parameter S1Pf/f L-S1P
Number and sex 5 males 5 males
S1P mRNA %a 100 ± 39.2 15 ± 8.4**
TC, mg/dl 68.8 ± 6.3 49.7 ± 5.3*
TG, mg/dl 52.7 ± 10.7 36.9 ± 7.5*
Blood was obtained from non-fasted male mice (6–8 weeks of age) as described
in Methods. Each value represents the mean ± the SD of five mice. The statistical
significance (Student’s t test) between S1Pf/f and L-S1P was calculated.
*P < 0.05; and **P < 0.01. afull length S1P mRNA expression is expressed as
a % of the corresponding S1Pf/f value
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control mice. Four-hour fasted mice were injected intra-
peritoneally with P407 and blood was collected over a
period of 6 h. P407 inhibits lipoprotein lipase, endothelial
lipase and hepatic lipase activities, preventing the degrad-
ation of plasma TG-rich lipoproteins [11]. Since, VLDL
particles are mainly TG rich, we measured plasma TG
levels at different time points. As shown in Fig. 1c, signifi-
cantly less TG was secreted in S1Pf/f Cre than in control
animals. This in vivo experiment showed that hepatic S1P
modulates VLDL secretion and hence plasma lipids.
To determine which lipoprotein fractions are affected
by hepatic S1P KD, pooled plasma samples from the
fasted mice in each group were fractionated by FPLC
and cholesterol and TG concentrations were measured
in different fractions. Hepatic S1P KD produced similar
relative decreases in both HDL-c (Fig. 1d) and Blp TGs
(Fig. 1e). However, hepatic S1P KD had a minimal effect
on plasma Blp cholesterol (Blp-c) (Fig. 1d), despite the
significant reduction it produced in VLDL secretion
(Fig. 1c). Similar results were obtained when the experi-
ment was repeated on three other occasions.
Hepatic S1P deficiency resulted in discordance between
LDLR mRNA and protein levels in mice fed ad libitum
To investigate why hepatic S1P KD had little effect
on plasma Blp-c levels, we first evaluated hepatic
LDLR expression which is a major regulator of LDL-c.
S1Pf/fLuci and S1Pf/fCre mice in the ad libitum fed state
(Fig. 2). Hepatic S1P KD (Fig. 2a, fed state) reduced
hepatic LDLR mRNA by 50 % (Fig. 2b, fed state).
This is in agreement with earlier studies using mice
in the fed state [6, 8]. Despite this reduction in LDLR
mRNA, liver LDLR protein levels in ad libitum fed
S1Pf/fCre mice were similar to those of S1Pf/fLuci
control mice (Fig. 2c and d, fed state).
When S1Pf/fLuci and S1Pf/fCre mice were fasted over-
night, levels of hepatic LDLR mRNA in S1Pf/fCre mice
were reduced compared with control mice (Fig. 2b, fasted
state) to an extent similar to that found in ad libitum
feeding conditions (Fig. 2b, fed state). However, LDLR
protein levels in the fasted state in S1Pf/fCre mice
were significantly lower than that of the control mice
(Fig. 2e and f ). Similar results were obtained when
mice were fasted for 4 h (data not shown). Therefore,
hepatic S1P KD results in reduced LDLR function by
decreasing LDLR mRNA transcription, which in the
fasting state leads to reduced LDLR protein expression.
The above results provide an explanation for why hepatic
S1P KD has a minimal effect on plasma Blp-c levels in
S1Pf/fCre mice fasted for four hours (Fig. 1d). Hepatic S1P
KD decreases VLDL secretion (Fig. 1c) in fasted mice,
which leads one to expect a reduction in plasma Blp-c
levels. However, hepatic S1P KD reduces LDLR protein
expression in these mice (Fig. 2e), which would impair
uptake of Blp particles and thus normalize Blp-c levels.
Hepatic S1P deficiency regulates LDLR protein levels
post-translationally After observing the discordance
between LDLR mRNA and protein levels in ad libitum
fed S1P deficient mice, we hypothesized that hepatic
S1P also regulates LDLR protein levels at the post-
translational level. We generated a plasmid expressing
the murine LDLR with an added N-terminal Gaussia
luciferase, designated Gau-LDLR, controlled by the
CMV promoter (Fig. 3a). The resultant fusion protein
was used to monitor the turnover of endogenous LDLR
protein. Expression of the Gau-LDLR fusion protein was
verified in Huh7 cells using immunoblotting (Fig. 3b). In
vitro DiI-labeled LDL binding and uptake assays confirmed
that the Gau-LDLR protein was functional (Fig. 3c and d).
To assess post-translational regulation of the LDLR in
vivo, we created a dual reporter assay by transducing
mice with Ad-Gau-LDLR in combination with Ad-
Firefly luciferase (Ad-Luci): the latter to serve as a con-
trol for transduction efficiency. The assay was carried
out in liver homogenates from S1Pf/fEmpty and S1Pf/fCre
mice fed ad libitum. A higher ratio of Gaussia/Firefly lu-
ciferase activities was obtained in the supernatants of
S1Pf/fCre liver homogenates compared with those from
S1Pf/fEmpty, indicating a greater total LDLR protein
stability in S1P deficient mice livers (Fig. 3e).
Hepatic S1P KD decreases PCSK9 expression To in-
vestigate how S1P KD enhances hepatic LDLR protein
stability, we measured hepatic mRNA levels of several
post-translational regulators of LDLR protein in the
presence and absence of S1P KD. Inducible degrader of
the LDLR (IDOL) [20] and Autosomal Recessive Hyper-
cholesterolemia (ARH, [22]) mRNA levels were not al-
tered when S1P was knocked down (Fig. 4a and b).
Since PCSK9 protein degrades the LDLR [23, 24], we
determined the effect of hepatic S1P KD on PCSK9 ex-
pression in mice in two conditions: following ad libitum
feeding and after overnight fasting. S1P deficiency reduced
the levels of liver PCSK9 mRNA and plasma PCSK9 pro-
tein in S1Pf/fCre compared with S1Pf/fLuci animals in both
conditions (Fig. 4c and d). However, the reduction was
greater after ad libitum feeding than after fasting (PCSK9
mRNA: 13- versus 5-fold reduction, p < 0.05; PCSK9 pro-
tein: 8.3- versus 4.5-fold reduction, p < 0.05). These results
indicate that hepatic S1P KD more significantly decreases
PCSK9 expression in the fed state. This would reduce
PCSK9-mediated LDLR protein degradation in the S1P
KD mice livers and normalize LDLR protein to that of
control mice in the fed state than in fasting conditions.
Thus, the observed greater reduction in plasma PCSK9
protein after hepatic S1P KD in the fed state provides an
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explanation for the discordance between LDLR mRNA
and protein expression in the fed state (Fig. 2b, c and d).
Hepatic S1P KD decreases PCSK9 expression at the
transcriptional level To test whether S1P deficiency in-
fluenced PCSK9 mRNA stability as opposed to rate of
transcription, transcription was blocked using actinomy-
cin D in primary murine hepatocytes from S1Pf/fLuci
and S1Pf/fCre mice. As shown in Fig. 5a, the PCSK9
mRNA decay curves of these groups were similar, indi-
cating that hepatic S1P KD did not alter PCSK9 mRNA
stability.
To determine whether hepatic S1P deficiency affects
the synthesis rate of PCSK9 mRNA, nuclear run-on as-
says were carried out in primary murine hepatocytes
from S1Pf/fLuci and S1Pf/fCre mice. Hepatic S1P KD sig-
nificantly reduced the amount of newly synthesized
PCSK9 pre-mRNA (Fig. 5b), indicating that hepatic S1P
controls the rate of PCSK9 mRNA synthesis. Consistent
with this result, two murine PCSK9 promoter activities
were significantly lower in S1Pf/fCre hepatocytes than in
control cells (Fig. 5c and d).
A common pathway accounts for PCSK9 regulation
by the SREBPs and S1P Since S1P is not itself a tran-
scription factor, these results strongly indicate that S1P
controls the activity of a transcription factor(s) that influ-
ence(s) PCSK9 mRNA synthesis. S1P KD has been re-
ported to block SREBP1 and SREBP2 activation [6]. The
downregulation of SREBP1c and SREBP2 mRNA expres-
sion levels, and the mRNAS of two of their downstream
targets, fatty acid synthase and acetyl CoA carboxylase,
were confirmed in S1Pf/fCre mice (data not shown).
To determine the role of the SREBPs in regulation of
PCSK9 by S1P, SREBP1 and SREBP2 in combination were
knocked down using siRNAs in primary S1Pf/fLuci hepato-
cytes and S1Pf/fCre hepatocytes. Using hepatocytes trans-
fected with a non-targeting scrambled siRNA as controls,
efficient KD of SREBP1 and SREBP2 was confirmed in both
hepatocyte types. The knockdown efficiency of SREBP1
Fig. 2 Comparison of mRNA and protein levels of the LDLR in the livers of S1Pf/f Luci and S1Pf/fCre mice ad libitum fed or fasted as
described in the Methods Section. 6–8 weeks female mice were sacrificed at 9 AM. a, Hepatic S1P mRNA; b, LDLR mRNA; c and d, LDLR
protein levels; e and f, quantification of the Western blots. N = 4, each data point is the mean +/- SD, *, denotes p < 0.05. ns, denotes
not significant
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and SREBP2 was 90–95 % in S1Pf/fLuci hepatocytes and
55–65 % in S1Pf/fCre hepatocytes. Since, S1Pf/fCre hepato-
cytes (siNTC group) already have a reduced expression of
SREBP1 and SREBP2 compared to S1Pf/fLuci hepatocytes
(siNTC group) due to reduced processing of SREBPs, we
think that the final knockdown of SREBP1 and SREBP2 is
equivalent in both control and cre hepatocytes.
Combined KD of SREBP1 and SREBP2 lowered PCSK9
mRNA in S1Pf/fLuci hepatocytes but not in S1Pf/fCre hepa-
tocytes (Fig. 6a and b), suggesting that S1P and the SREBPs
contribute to a common mechanism controlling PCSK9
transcription. KD of CREBH or ATF6α in S1Pf/fLuci
hepatocytes did not alter PCSK9 mRNA expression (data
not shown), indicating that S1P does not affect PCSK9
expression through CREBH or ATF6α.
The reduced PCSK9 expression seen in S1P deficiency
is restored by complementation of the SREBPs’
function If lack of activation of the SREBPs’ function is
responsible for the reduced PCSK9 mRNA levels seen in
S1P-deficient mice, complementation of the SREBPs’
function should restore PCSK9 mRNA levels. To test this,
a constitutively active form of SREBP1c, an N-terminal re-
gion of murine SREBP1c (N-SREBP1c) [25], was generated.
Fig. 3 LDLR protein is stabilized in S1Pf/f Cre mice livers. a, A schematic depicting the Gau-LDLR fusion protein reporter; b, Huh7 cells were transfected
with empty vector, wild-type LDLR or a Gau-LDLR plasmid. Forty-eight hours after transfection, cell lysates were collected and LDLR expression was
confirmed by immunoblotting; c and d, Another two sets of cells were subjected to DiI-LDL binding or uptake, respectively, as described in Materials
and Methods; e, Relative luciferase (Gaussia/Firefly) counts in livers of S1Pf/f Empty and S1Pf/fCre mice as a measure of total LDLR protein as described
in Material and Methods. Here Ad-Empty was used for S1P control mice as Ad-luciferase was administered in both control and S1P KD mice to serve
as the normalizing factor for injection. N = 3, each data point is mean +/- SD, * denotes p < 0.05
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Hepatocytes from S1Pf/fLuci and S1Pf/fCre mice were
transduced with Ad-Luci or Ad-N-SREBP1c. As shown
in Fig. 6c, N-SREBP1c overexpression restored PCSK9
mRNA levels in S1Pf/fCre cells to the levels seen in
S1Pf/fLuci cells. Similarly, using the same set of hepa-
tocytes, PCSK9 promoter activity was restored in
S1Pf/fCre cells to the levels seen in S1Pf/fLuci cells by
overexpression of N-SREBP1c (Fig. 6d).
Next, to determine if these results could be recapitu-
lated in vivo, three groups of ad libitum fed mice were
studied: (i) S1Pf/fLuci; (ii) S1Pf/fCre; (iii) S1Pf/fCre + N-
SREBP1c. When N-SREBP1c was overexpressed, mRNAs
for both SREBP1c and SREBP2 were elevated (Table 3).
As shown in Fig. 6e, the level of PCSK9 mRNA was
restored by N-SREBP1c overexpression in the livers of
S1P f/fCre mice (S1Pf/fCre + N-SREBP1c) compared with
those of S1Pf/fCre mice, p < 0.05) to an extent similar
to that exhibited by the control S1Pf/fLuci, (S1Pf/fCre + N-
SREBP1 versus S1Pf/fLuci, P > 0.05). Thus, hepatic
S1P KD reduces PCSK9 expression through lack of
activation of the SREBPs. As a result of the reduced
plasma PCSK9 protein levels, hepatic S1P KD en-
hances LDLR protein stability and maintains LDLR
protein levels despite the reduction in LDLR mRNA
expression.
Hepatic S1P KD significantly lowers Blp-c levels in
LDLR-/- mice To investigate whether hepatic S1P KD
could reduce the elevated plasma Blp-c levels found in
LDLR-/- mice, a line of hepatic S1P KD mice was gener-
ated in the LDLR deficient background. The KD of hep-
atic S1P mRNA was confirmed and was comparable to
that in the S1Pf/fCre mice (Table 1, line 1, columns 3
and 4). Presence of hepatic S1Pf/fCre in the LDLR defi-
cient background resulted in a 39 % and 31 % decrease
in TC (p < 0.05) and TG (p < 0.05) respectively (Table 1,
lines 2 and 3, columns 3 and 4). When the blood lipo-
proteins were analyzed by gel filtration, the relative de-
creases in both HDL-c and Blp TGs (Fig. 7a and b) were
found to be similar to those when hepatic S1Pf/fCre was
compared with S1Pf/fLuci (Fig. 1e and f). Significantly,
however, hepatic S1Pf/fCre in the LDLR deficient
background resulted in a significant reduction in plasma
Blp-c levels, in terms of both absolute and relative changes
(Fig. 7a), compared with the results when hepatic S1Pf/fCre
was compared with S1Pf/fLuci (Fig. 1e).
Fig. 4 Hepatic S1P KD and regulators of the LDLR. a and b: Hepatic mRNA analyses in S1Pf/fLuci and S1Pf/fCre mice using real-time PCR. a, Idol; b, ARH;
c and d: studies in the mouse models of Fig. 2: c, PCSK9 mRNA levels; d, Plasma PCSK9 protein levels quantified using ELISA. N = 4, each data
point represents the mean +/- SD * denotes p < 0.05. ns denotes not significant
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Discussion
Using multiple mouse models of hepatic S1P deficiency,
we have demonstrated a physiological role for hepatic S1P
in regulating plasma lipoprotein metabolism through
effects on the LDLR and PCSK9. The major findings are:
(i) KD of hepatic S1P (95 % reduction compared with
wild type or 75 % reduction compared with S1Pf/f
mice), resulted in 45 % and 38 % reduction in
plasma TC and TG levels, respectively.
(ii) Hepatic S1P deficiency results in discordance
between LDLR mRNA and protein expression due
to a post-translational stabilization of LDLR protein.
(iii) Hepatic S1P regulates PCSK9 expression through
the activation of the SREBPs.
(iv)The lack of normal S1P-PCSK9 regulation of LDLR
protein degradation in S1P deficient livers provides
an explanation for the discordance in LDLR mRNA
and protein expression.
(v) Hepatic S1P deficiency alone has a minimal effect
on Blp-c in the S1Pf/f background, but produces a
significant reduction in LDLR-/-mice.
Our study clearly demonstrates a unique role for hep-
atic S1P deficiency in regulating plasma Blp-c levels.
When the LDLR function is intact, hepatic S1P inhib-
ition has little effect on plasma Blp-c levels (Fig. 1d).
When the LDLR function is compromised, as occurs in
LDLR deficient mice, S1P inhibition potently (~50 %) re-
duces plasma Blp-c levels (Fig. 7a). Thus, hepatic S1P is
a valid target for lowering plasma Blp-c levels in the par-
ticular situation where LDLR function is compromised.
While the plasma lipid phenotype associated with hep-
atic S1P deficiency rather surprisingly is similar to that
of transgenic mice overexpressing the nuclear form of
SREBP1a in liver (SREBP1aTg mice) [26], the mecha-
nisms underlying the phenotypes are very different.
SREBP1aTg mice produce large lipid-rich lipoproteins.
However, these do not accumulate in plasma because
they are cleared through the action of the LDLR whose
function is enhanced by up-regulation of SREBP1a. In
hepatic S1P KD mice, the plasma Blp-c level, which one
would expect to drop as a result of reduced cholesterol
synthesis, is maintained due to the impaired function of
the LDLR in fasted mice. The doubly mutant SREBP1aTg
LDLR-/- mice exhibit marked increases in plasma Blp-c
and triglycerides [26], whereas LDLR-/- S1Pf/fCre mice
have decreased plasma Blp-c and triglycerides (Fig. 7).
These models and their phenotypes highlight the critical
role of the LDLR in Blp metabolism in response to
Fig. 5 S1P regulates the rate of PCSK9 transcription. a, Comparison of PCSK9 mRNA levels at the indicated time points in S1Pf/f Luci and S1Pf/fCre
hepatocytes after treatment with actinomycin D (10 μg/ml). n = 6, values plotted as % of the 0 h value; b, Comparison of nuclear synthesis of nascent
PCSK9 transcripts in S1Pf/f Luci and S1Pf/fCre hepatocytes using a run-on assay. Values are plotted as the mean of triplicate measurements from one
representative experiment. The experiment was repeated three times yielding similar results; c and d, PCSK9 promoter activities in
S1Pf/fLuci and S1Pf/fCre hepatocytes. N = 3, each data point represents the mean +/- SD, * denotes p < 0.001
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either activation or inhibition of the SREBP pathway.
Importantly, both activation and inactivation of the
SREBP pathway have a minimal impact on plasma Blp-c
levels when the LDLR regulation by the SREBPs is
intact.
In the work presented here, the maximum reduction
of plasma TC and TG that can be achieved through hep-
atic S1P inhibition is around 50 %. The same is likely
true for plasma Blp-c levels. This is very different from
inhibition of MTP and apoB, which can produce more
profound reductions of plasma Blp-c levels [27, 28].
However hepatic S1P inhibition has a significant advan-
tage over these two approaches, i.e., it is not accompan-
ied by hepatic lipid accumulation. One interesting
question is whether hepatic S1P KD has a more pro-
found effect on plasma Blp-c levels in mice on a high fat
diet. Hepatic SREBP cleavage-activating protein (Scap)
gene deletion [29] and Scap protein inhibition by betulin
[30] showed that this is indeed the case.
Although SREBPs have been implicated in PCSK9
regulation [13] and S1P controls SREBP activation, we
took an unbiased approach to dissect the regulation of
PCSK9 by S1P for several reasons: (i), S1P could poten-
tially regulate other transcriptional factors that might
also affect PCSK9 mRNA expression; (ii), PCSK9 mRNA
is regulated by other coactivators such as hepatic nuclear
factor 1α [31, 32]; (iii), PCSK9 protein maturation is in-
fluenced by other factors [33]. Under the experimental
conditions of this study, we conclude that hepatic S1P
mainly regulates plasma PCSK9 levels through control-
ling SREBPs’ activation.
The maintenance of the endogenous LDLR protein
level in S1P deficient mouse livers at the level deter-
mined for control mice in the ad libitum fed condition
(Fig. 2d) can be explained by the increased LDLR protein
stability found for the S1P deficient mice, shown in
Fig. 3e. Since S1P deficiency reduces plasma PCSK9
levels (Fig. 4d), we believe that the lack of normal S1P-
originating production of PCSK9 in such mice is respon-
sible for the discordance in LDLR mRNA (lowered) and
protein levels (maintained) seen in the S1P deficient
livers (Fig. 2b, d). The S1P-PCSK9 regulation is more
prominent in the fed state, which makes sense in terms
Table 3 SREBP1 and SREBP 2 gene expression in livers of mice
with SREBP1c-N overexpression
Parameter S1Pf/fLuci S1Pf/fCre S1Pf/fCre + N-SREBP1c
Number and sex 4 males 4 males 4 males
SREBP1c mRNA %# 100 ± 14 43 ± 9 392 ± 42*
SREBP2 mRNA %# 100 ± 27 50 ± 5.3 88 ± 13*
Hepatic mRNA levels of SREBP1c and SREBP2 in the experiment presented in
Fig. 6e. Each value represents the mean ± the SD of 4 mice. The statistical
significance (Student’s t test) between S1Pf/fCre and S1Pf/fCre + N-SREBP1c
was calculated. *P < 0.05 #mRNA expression is expressed as a % of the
corresponding S1Pf/f Luci value
Fig. 6 A molecular mechanism for regulation of PCSK9 by hepatic S1P. a and b, Primary hepatocytes (S1Pf/f Luci or S1Pf/fCre) were transfected
with non-targeting control siRNA (siScr) or SREBP1 + 2 siRNA (siSREBP1 + 2) and cells were harvested 56 h post transfection for RNA isolation.
PCSK9 mRNA quantification after combined KD of SREBP1 and SREBP2 in S1Pf/f Luci hepatocytes (a), and S1Pf/fCre hepatocytes (b). N = 3, each
data point represents a mean +/- SD, * denotes p < 0.05, ns denotes non significant. All values plotted as % of siScr control; (c and d), PCSK9
mRNA levels (c) and PCSK9 promoter activity (d) were measured in S1Pf/f Luci and S1Pf/fCre hepatocytes after transduction with either Ad-Luci or
Ad N-SREBP1c. N = 3, each data point represents a mean +/- SD, * denotes p < 0.05, ns denotes non significant. All values plotted as % of S1Pf/f
Luci control; (e) Hepatic PCSK9 mRNA levels were measured in three groups of mice: i) S1Pf/f Luci (transduced with 10 viral particles of Ad-Luci
per mouse); ii) S1Pf/f Cre (transduced with 5×1010 viral particles of Ad-Cre and 5×1010 viral particles of Ad-Luci per mouse); iii) S1Pf/fCre + N-
SREBP1c (transduced with 5×1010 viral particles of Ad-Cre and 5×1010 viral particles of Ad-N-SREBP1c per mouse). Mice were fed ad libitum. N =
3–4, each data point represents a mean +/- SD, * denotes p < 0.05, ns denotes not significant. All values plotted as % of S1Pf/f Luci control
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of the higher level of circulating PCSK9 present in con-
trol mice in the fed state (Fig. 4d and [34]). Further stud-
ies are required to examine whether lowering of PCSK9
function is solely responsible for the effect on LDLR
protein in the S1P deficient mice.
Our results also reveal a complex role for hepatic S1P
in regulation of LDLR function and plasma Blp-c levels.
On the one hand, hepatic S1P KD decreases LDLR
mRNA expression through reducing the SREBPs, and on
the other hand, increases LDLR protein levels through
down-regulation of PCSK9 expression, again, mediated
through the SREBPs. The net effect of hepatic S1P KD
on LDLR level/function is unfavourable under fasting
conditions (Fig. 2f ). A similar type of regulation likely
exists for plasma Blp-c metabolism. Hepatic S1P KD is
known to decrease cholesterol biosynthesis which would
likely decrease VLDL secretion, at the same time redu-
cing VLDL/LDL clearance through lowered levels of the
LDLR. Thus the net effect of hepatic S1P KD on plasma
Blp-c is minimal. It is possible that these results may
also be obtained using inhibitors of the SREBP pathway
other than S1P KD.
To differentiate the effect of S1P on LDLR mRNA
from its effect on LDLR protein stability, we developed a
novel and sensitive in vivo LDLR reporter assay to meas-
ure LDLR protein turnover. The assay, which is modeled
on the conventional dual reporter assay for promoter
analysis, is feasible, because fusion of Gaussia luciferase
with the LDLR did not affect LDLR location and func-
tion. In light of the recent discovery of novel modulators
of LDLR protein turnover, such as IDOL, Annexin A2,
ARH and Rab5 [20, 22, 35, 36], we envision that this
LDLR protein reporter assay could have broad applica-
tions. With some modifications, the assay could be used
to determine the kinetics of LDLR protein turnover
since it can differentiate endogenous from exogenous
Fig. 7 Hepatic S1P KD reduced plasma Blp-c levels in LDLR-/- mice. a and b, S1Pf/fLDLR-/- Luci and S1Pf/fLDLR-/-Cre mice. Lipid measurements were
carried out on gel filtration fractions from pooled plasma samples of mice in two mouse models of hepatic S1P KD mice. Female mice (N = 4, 6–8
weeks of age) were transduced with the indicated adenoviruses. This experiment was repeated three times and similar results were obtained
Fig. 8 A working model of S1P regulation of plasma Blp-c levels
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LDLR. This reporter system would also permit identifi-
cation and validation of novel post-translational modula-
tors of LDLR in vivo.
Inhibition of hepatic S1P has been shown to reduce
plasma TC and TG levels [6, 8]. Apart from the known
decreased lipid de novo synthesis, it was not apparent that
there was an additional mechanism(s) by which S1P inhib-
ition lowered plasma lipids. Here we show that hepatic S1P
deficiency reduces hepatic PCSK9 expression and thus
degradation of the LDLR. Because PCSK9 has been shown
to be involved in VLDL secretion [37], further studies are
required to determine whether hepatic S1P KD also re-
duces VLDL secretion through inhibition of PCSK9.
Conclusions
In summary, our studies clearly demonstrate the physio-
logical role of hepatic S1P deficiency in PCSK9 and
LDLR regulation under various conditions. Hepatic S1P
deficiency represses activation of the SREBP proteins. A
reduced number of activated SREBPs then bind the
LDLR and PCSK9 gene promoters, resulting in less tran-
scription of their mRNAs and reduced plasma PCSK9
protein levels. The reduction of PCSK9 mRNA and pro-
tein is more prominent in the fed state, which likely con-
tributes to the increased LDLR protein stability and the
maintenance of hepatic LDLR protein levels despite the
reduced LDLR mRNA. In the fasting state, hepatic S1P
KD has less effect on plasma PCSK9 concentrations and
as a result, liver LDLR protein levels are lower (Fig. 8).
These regulatory processes are critical for fine-tuning
both LDLR protein at the post-translational level and
plasma Blp-c levels.
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